MedTrace Logo

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-05-05

No results posted yet for this study

Summary

Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.

Conditions

  • Healthy

Interventions

DRUG

Atenolol 50 MG

50 mg Atenolol daily

DRUG

Placebo

one placebo daily

Sponsors & Collaborators

Principal Investigators

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2026-02-02
Completion
2026-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04905277 on ClinicalTrials.gov